EPO and Hypocalcemia: In our previous study [20], supportive therapy (antiemetics, erythropoietins, colony-stimulating growth factors, and hypocalcemia medications) accounted for 4.6% of the total pharmaceutical expenditure for the treatment of solid tumors in patients treated in the routine healthcare setting, and although this percentage is low, it showed a decreasing trend along the years, with only 1.4% in 2019.